Evidence map›Paper›PMID 34482255›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2021

Endochin-like quinolones (ELQs) and bumped kinase inhibitors (BKIs): Synergistic and additive effects of combined treatments against Neospora caninum infection in vitro and in vivo.

Nicoleta Anghel, Dennis Imhof, Pablo Winzer, Vreni Balmer, Jessica Ramseier, Kai Haenggeli, Ryan Choi, Matthew A Hulverson, Grant R Whitman, Samuel L M Arnold and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Microorganisms · 2026
    Review
  2. Article
  3. Article
  4. Synthesis of Deuterated Endochin-Like Quinolones.Journal of labelled compounds & radiopharmaceuticals · 2024
    Article
  5. Article
  6. Article
  7. Dual inhibition of theFrontiers in veterinary science · 2022
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Nicoleta AnghelInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, Switzerland. Electronic address: nicoleta.anghel@vetsuisse.unibe.ch.
Dennis ImhofInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, Switzerland.
Pablo WinzerInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, Switzerland.
Vreni BalmerInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Switzerland.
Jessica RamseierInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Switzerland.
Kai HaenggeliInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Switzerland; Graduate School for Cellular and Biomedical Sciences (GCB), University of Bern, Switzerland.
Ryan ChoiCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Matthew A HulversonCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Grant R WhitmanCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Samuel L M ArnoldCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Department of Pharmaceutics, University of Washington, Seattle, WA, USA.
Kayode K OjoCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Wesley C Van VoorhisCenter for Emerging and Re-emerging Infectious Diseases (CERID), Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; Departments of Global Health and Microbiology, University of Washington, Seattle, WA, USA.
J Stone DoggettVA Portland Health Care System, Research and Development Service, Portland, OR, USA.
Luis M Ortega-MoraSALUVET, Animal Health Department, Faculty of Veterinary Sciences, Complutense University of Madrid, Ciudad Universitaria s/n, Madrid, Spain.
Andrew HemphillInstitute of Parasitology, Vetsuisse Faculty, University of Bern, Switzerland. Electronic address: andrew.hemphill@vetsuisse.unibe.ch.
University of Bern · CHUniversity of Washington · USUniversidad Complutense de Madrid · ESVA Portland Health Care System · US

Funding

Bumped Kinase Inhibitors: Novel Therapeutics for Cryptosporidiosis&ToxoplasmosisR01AI111341 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$6.4M
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvumR01AI089441 · NIAID · UNIVERSITY OF WASHINGTON · PI MERRITT, ETHAN A, PARSONS, MARILYN · 2010 to 2014
$5.0M
Optimization of Lead BKIs for Cryptosporidiosis TherapyR01AI155412 · NIAID · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$4.1M
Bumped-Kinase Inhibitor Drug Development for ToxoplasmosisR01HD102487 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$3.3M
Dual Use Therapeutics for Cryptosporidiosis, Toxoplasmosis, and NeosporosisR01HD080670 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2014 to 2018
$1.9M
Coformulation of bumped kinase inhibitors with Artemisinin combination therapy will stop widespread transmission of artemisinin-resistant malaria strainsR21AI123690 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2017 to 2018
$490k
Development of Dual Efficacy Therapeutic Against Cryptosporidiosis and GiardiasisR21AI140881 · NIAID · UNIVERSITY OF WASHINGTON · PI OJO, KAYODE K · 2019 to 2020
$477k
BLRD VA I01 BX004522NIAID NIH HHS R01 AI089441NIAID NIH HHS R01 AI111341NIAID NIH HHS R01 AI155412NIAID NIH HHS R21 AI123690NIAID NIH HHS R21 AI140881NICHD NIH HHS R01 HD080670NICHD NIH HHS R01 HD102487
6 · The paper itself

Abstract

The apicomplexan parasite Neospora caninum is an important causative agent of congenital neosporosis, resulting in abortion, birth of weak offspring and neuromuscular disorders in cattle, sheep, and many other species. Among several compound classes that are currently being developed, two have been reported to limit the effects of congenital neosporosis: (i) bumped kinase inhibitors (BKIs) target calcium dependent protein kinase 1 (CDPK1), an enzyme that is encoded by an apicoplast-derived gene and found only in apicomplexans and plants. CDPK1 is essential for host cell invasion and egress; (ii) endochin-like quinolones (ELQs) are inhibitors of the cytochrome bc

Indexed as

CoccidiosisNeosporaParasitesQuinolonesAnimalsCattleFemaleMiceMice, Inbred BALB CPregnancySheepQuinolonesAntiparasitic therapyBumped kinase inhibitorsCalcium-dependent protein kinase inhibitorCombination therapyCytochrome bc(1)Endochin-like quinolonesNeosporosisTachyzoites

Identifiers

PMID34482255
PMCPMC8416643
OpenAlexW3197353458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.